Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor.
Takayuki KatsubeSafwan KezborRyosuke ShimizuRyuji KubotaPublished in: Infectious diseases and therapy (2024)
Ensitrelvir was well tolerated by participants with renal impairment. There was no clinically meaningful increase on exposure to ensitrelvir in participants with renal impairment, indicating that no dose adjustment would be required due to renal function.
Keyphrases